Monaca Federico, Vita Emanuele, Lococo Filippo, Tortora Giampaolo, Bria Emilio
Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS (Scientific Institute for Research, Hospitalization and Healthcare), Rome, ITA.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS (Scientific Institute for Research, Hospitalization and Healthcare), Rome, ITA.
Cureus. 2024 Jul 23;16(7):e65186. doi: 10.7759/cureus.65186. eCollection 2024 Jul.
In recent years, the widespread use of next-generation sequencing (NGS) allowed clinicians to identify and treat non-small cell lung cancer (NSCLC) efficiently with target therapy. RET inhibitors, like selpercatinib and pralsetinib, for RET rearrangements in lung cancer showed high efficacy and clinical benefit. Nevertheless, to date, the use of molecular-targeted agents has not been tested in all lung cancer subtypes. Indeed, pulmonary sarcomatoid carcinoma (PSC) remains a rare form of NSCLC, unresponsive to standard chemotherapy, and associated with extremely poor prognosis. We report the first case of a patient affected by RET fusion-positive PSC with a bleeding colic metastasis and a consequent poor performance status who achieved a dramatic response to selpercatinib and a remarkable clinico-radiological benefit.
近年来，下一代测序（NGS）的广泛应用使临床医生能够通过靶向治疗有效识别和治疗非小细胞肺癌（NSCLC）。针对肺癌中RET重排的RET抑制剂，如塞尔帕替尼和普拉替尼，显示出高疗效和临床获益。然而，迄今为止，分子靶向药物尚未在所有肺癌亚型中进行测试。事实上，肺肉瘤样癌（PSC）仍然是NSCLC的一种罕见形式，对标准化疗无反应，且预后极差。我们报告了首例RET融合阳性PSC患者，该患者伴有出血性结肠转移且体能状态较差，对塞尔帕替尼产生了显著反应，并在临床影像学上获得了明显益处。
